Diarylheptanoid‐flavanone Hybrids as Multiple‐target Antidiabetic Agents from <i>Alpinia katsumadai</i>
Xiaofeng He, Ji‐Jun Chen, Tian‐Ze Li, Jing Hu, Xiaoyan Huang, Xue‐Mei Zhang, Yuanqiang Guo, Chang‐An Geng
Abstract
Main observation and conclusion The EtOAc fraction of Alpinia katsumadai seeds showed significant inhibition on glycogen phosphorylase a (GPa) with inhibitory ratios of 97.9% and 64.6% at concentrations of 200 and 100 μg/mL, respectively. Bioactivity‐guided isolation afforded 15 new diarylheptanoid‐flavanone hybrids, katsumadainols B 1 —B 15 (1—15), together with eight known ones (16—23). Compounds 4—10 and 12—21 exhibited activity against GPa with IC 50 values of 10.1—95.4 μmol/L; compounds 4, 5, 16, and 17 displayed inhibitory effects on α ‐glucosidase with IC 50 values of 7.1, 12.4, 7.2, and 8.3 μmol/L, obviously higher than acarbose (IC 50 , 209.1 μmol/L); compounds 4—6, 14, 16—20, 22, and 23 were PTP1B/TCPTP selective inhibitors with IC 50 values of 40.7—95.8 μmol/L; compounds 4, 5, 16, and 17 showed DPP4 inhibitory effects with inhibitory ratios of 50.0%—54.2% (200 μmol/L). Diarylheptanoid‐flavanone hybrids (4, 5, 16, and 17) with a p ‐hydroxybenzyl at C‐6 position represent a promising class of multiple‐target antidiabetic agents inhibiting GPa, α ‐glucosidase, PTP1B, and DPP4.